287 related articles for article (PubMed ID: 16405921)
1. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
2. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
3. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
4. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
5. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
Shin JM; Cho YM; Sachs G
J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
8. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
9. Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Buhr W; Brehm C; Palmer AM; Feth MP; Senn-Bilfinger J; Simon WA
Bioorg Med Chem Lett; 2007 Oct; 17(19):5374-8. PubMed ID: 17723299
[TBL] [Abstract][Full Text] [Related]
10. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
11. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.
Hunt RH; Armstrong D; James C; Chowdhury SK; Yuan Y; Fiorentini P; Taccoen A; Cohen P
Am J Gastroenterol; 2005 Sep; 100(9):1949-56. PubMed ID: 16128938
[TBL] [Abstract][Full Text] [Related]
12. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Besancon M; Simon A; Sachs G; Shin JM
J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.
Gedda K; Briving C; Svensson K; Maxvall I; Andersson K
Biochem Pharmacol; 2007 Jan; 73(2):198-205. PubMed ID: 17081503
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.
Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725
[TBL] [Abstract][Full Text] [Related]
15. Restoration of acid secretion following treatment with proton pump inhibitors.
Shin JM; Sachs G
Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology of the gastric acid pump: the H+,K+ ATPase.
Sachs G; Shin JM; Briving C; Wallmark B; Hersey S
Annu Rev Pharmacol Toxicol; 1995; 35():277-305. PubMed ID: 7598495
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the gastric H+,K+ -ATPase by plectrinone A, a diterpenoid isolated from Plectranthus barbatus Andrews.
Schultz C; Bossolani MP; Torres LM; Lima-Landman MT; Lapa AJ; Souccar C
J Ethnopharmacol; 2007 Apr; 111(1):1-7. PubMed ID: 17166678
[TBL] [Abstract][Full Text] [Related]
18. 2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors.
Yamada M; Yura T; Morimoto M; Harada T; Yamada K; Honma Y; Kinoshita M; Sugiura M
J Med Chem; 1996 Jan; 39(2):596-604. PubMed ID: 8558532
[TBL] [Abstract][Full Text] [Related]
19. [Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
Nagaya H; Satoh H
Nihon Rinsho; 1992 Jan; 50(1):26-32. PubMed ID: 1311786
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
Wallmark B; Lorentzon P; Larsson H
Scand J Gastroenterol Suppl; 1985; 108():37-51. PubMed ID: 2988109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
